JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-06-30 pm EDT
177.51 USD   +0.29%
08:22aJanssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
AQ
03:45aHywin Holdings, FactSet Launch Global Health Care Index
MT
06/29NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mariners put RHP Steckenrider on restricted list, add Elías

05/16/2022 | 04:03pm EDT

TORONTO (AP) — The Seattle Mariners put Drew Steckenrider on the restricted list before Monday’s opener of a three-game series at the Toronto Blue Jays, a move that could cost the right-hander $51,099 of his $3.1 million salary.

To enter the country, the Canadian government requires a person to have received a second COVID-19 vaccine dose — or one dose of Johnson & Johnson — at least 14 days before entry.

Players who go on the restricted list because they are not vaccinated against COVID-19 are not paid and do not accrue major league service time, according to a March agreement between Major League Baseball and the players' association.

Steckenrider is 0-1 with two saves and a 4.85 ERA in 14 relief appearances. The series is Seattle’s only regular-season visit to Toronto.

Seattle selected the contract of left-hander Roenis Elías from Triple-A Tacoma. He had joined the Mariners at Citi Field on Sunday in anticipation of being added to the active big league roster.

Elías signed a minor league contract with the Mariners on April 1. He previously pitched for Seattle in 2014 and ‘15, and again in 2018 and ’19. He also has pitched for Boston and Washington.

Elías, 33, last pitched in the majors with the Nationals in 2019. He had a 4.30 ERA in one start and 10 relief appearances at Triple-A Tacoma, striking out 11 and walking four in 14 2/3 innings.

___

More AP MLB: https://apnews.com/hub/MLB and https://twitter.com/AP_Sports

© 2022 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about JOHNSON & JOHNSON
08:22aJanssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for..
AQ
03:45aHywin Holdings, FactSet Launch Global Health Care Index
MT
06/29NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
06/29Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
MT
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
06/24JOHNSON & JOHNSON'S JANSSEN : CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
DJ
06/23JOHNSON & JOHNSON : Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 505 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,7x
Yield 2022 2,51%
Capitalization 467 B 467 B -
EV / Sales 2022 4,75x
EV / Sales 2023 4,47x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 177,51 $
Average target price 187,28 $
Spread / Average Target 5,50%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.46%465 732
ELI LILLY AND COMPANY16.94%290 752
PFIZER, INC.-14.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.84%272 382
NOVO NORDISK A/S7.29%251 811